Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02285088 | A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease | PHASE1 | COMPLETED | 133 | — | — | Dec 1, 2014 | May 1, 2017 | Feb 14, 2018 | - | — |
| Name | Type | Description |
|---|---|---|
| GBT440 | DRUG | GBT440 will be administered as oral capsules |
| Placebo | DRUG | Matching placebo will be administered as oral capsules |